Comparison of bortezomib with dexamethasone and thalidomide with dexamethasone in the treatment of patients with monoclonal immunoglobulin deposition disease.
Aug 2026· JN. Journal of Nephrology (Milano. 1992)· 0 citations
Medicine
TL;DR
Bortezomib/dexamethasone followed by autologous stem cell transplantation is recommended for transplant-eligible patients, while bortezomib/dexamethasone alone remains effective for those who are ineligible, which supports bortezomib/dexamethasone as first-line therapy.
BACKGROUND
The study aimed to evaluate the efficacy and safety of eculizumab in addition to conventional therapy for anti-glomerular basement membrane (anti-GBM) disease presenting rapidly progressive glomerulonephritis (RPGN).
METHODS
42 patients with anti-GBM disease presenting with RPGN were included in this multi...
Xia-Bing Lang, Xi-Zhen Hong, Wei-Fei Wu et al.· Nephrology, Dialysis and Tra...· 0 citations
Multiple myeloma (MM) is a common hematological malignancy. The high efficacy of the VTD induction regimen (bortezomib, thalidomide, dexamethasone) is limited by dose-dependent adverse reactions of thalidomide.
Objective. To evaluate the effect of a thalidomide dose-escalation strategy in the VTD regimen on efficac...
J. M. Al-Nsour, Vitalii B. Kaliberdenko, Amina R. Ablaeva et al.· Clinical review for general...· 0 citations
BACKGROUND
Complement-dependent cytotoxicity (CDC) of CD38 monoclonal antibodies has been associated with infusion-related reactions and might contribute to reduced clinical efficacy of CDC-reliant CD38 antibodies, particularly in patients with relapsed or refractory multiple myeloma with 1q21+. We aimed to evaluate fe...
Hai-Yan He, J. Shang, Ya-Fei Wang et al.· The Lancet Haematology· 0 citations
Teclistamab, a B cell maturation antigen-targeting bispecific antibody, has demonstrated substantial activity in relapsed multiple myeloma (MM), particularly in earlier lines of therapy, and may have higher efficacy in high-risk smoldering MM (HR-SMM) with a more functional immune system. In the randomized phase 2 Immu...
Omar Nadeem, D. M. Cordas dos Santos, Sophie Magidson et al.· Nature Medicine· 0 citations
Adding bortezomib did not demonstrate a significant efficacy benefit and was associated with a higher incidence of serious adverse events, which was associated with a higher incidence of serious adverse events.
R. Snanoudj, F. Marquant, Karine Renaudin et al.· Transplant International· 0 citations
Frontline DRd demonstrated favorable effectiveness and clinically meaningful treatment durability in patients aged > 80 years with Ti-NDMM and exploratory analyses suggested that a lower baseline PNI may be associated with severe infectious complications and a shorter treatment durability.
Yuichi Horigome, Koichi Ehata, N. Tadera et al.· Blood Research· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
